Venetoclax, a BCL-2 inhibitor with high oral bioavailability, has significantly improved the treatment landscape for leukemia, particularly CLL/SLL and AML, by overcoming anti-apoptotic mechanisms and achieving high remission rates and sustained responses. The gene discussed is BCL2; the disease is leukemia.